Clinical and biological predictors of response to standardised paediatric colitis therapy (PROTECT): a multicentre inception cohort study
Pediatric patients aged 4-17 years with newly diagnosed ulcerative colitis were recruited from 29 centers in the USA and Canada. The primary outcome was week 52 corticosteroid-free remission with no therapy beyond mesalazine.
